Bank Julius Baer & Co. Ltd Zurich Invests $79,000 in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,531 shares of the company’s stock, valued at approximately $79,000.

A number of other hedge funds also recently modified their holdings of the stock. Farther Finance Advisors LLC increased its holdings in Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after buying an additional 137 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of Dr. Reddy’s Laboratories during the 3rd quarter valued at approximately $60,000. Van ECK Associates Corp grew its holdings in shares of Dr. Reddy’s Laboratories by 64.3% during the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after purchasing an additional 322 shares during the last quarter. POM Investment Strategies LLC grew its holdings in Dr. Reddy’s Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after acquiring an additional 1,820 shares during the last quarter. Finally, Glenmede Trust Co. NA bought a new stake in Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $207,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Up 0.0 %

Shares of NYSE RDY opened at $12.71 on Wednesday. The company has a market capitalization of $10.61 billion, a P/E ratio of 20.23 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 52-week low of $12.62 and a 52-week high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company’s 50 day moving average price is $14.12 and its 200-day moving average price is $14.90.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RDY shares. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.